Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
| Distributed by / for | Golden State Medical Supply Inc. |
| NDC | 60429-318-90 |
| Full product label | Losartan Potassium Tablets USP 100 mg 90 count bottle NDC 60429-318-90 Rx only GSMS Incorporated |
| Recalling firm | Golden State Medical Supply Inc. |
| Distribution | IL, MI, MN, PA, TN, TX. Two (2) US government and one (1) Veterans Affairs accounts. No foreign accounts. |
| Quantity | 138,213 HDPE Bottles |
| Recall initiated | 2019-05-01 |
| Report date | 2019-05-29 |
| Recall completed | 2020-02-25 |
| Recall number | D-1285-2019 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Camarillo CA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗